Alder Surges as Drug Meets Migraine Goals in Mid-Stage TrialBy
Shares rise as much as 62%, biggest intraday gain ever
Drugmakers are racing to get migraine therapies to market
Alder Biopharmaceuticals Inc. rose as much as 62 percent, its biggest intraday gain ever, after saying that its experimental infusion to prevent migraines met the main goals of a mid-stage trial.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.